Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (<scp>CLL2‐BCG</scp>): Final analysis of a multicenter, open‐label <scp>phase‐II</scp>‐trial - KIVIRID

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (<scp>CLL2‐BCG</scp>): Final analysis of a multicenter, open‐label <scp>phase‐II</scp>‐trial

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27304

Keywords:

Abstract:

Source: